Relevant bibliographies by topics / Xanthines – therapeutic use

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books

Academic literature on the topic 'Xanthines – therapeutic use'

Author: Grafiati
Published: 4 June 2021
Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Xanthines – therapeutic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Xanthines – therapeutic use"

1

Cazzola, Mario, Luigino Calzetta, Peter J. Barnes, Gerard J. Criner, Fernando J. Martinez, Alberto Papi, and Maria Gabriella Matera. "Efficacy and safety profile of xanthines in COPD: a network meta-analysis." European Respiratory Review 27, no. 148 (May 2, 2018): 180010. http://dx.doi.org/10.1183/16000617.0010-2018.

Full text
Abstract:
Theophylline can still have a role in the management of stable chronic obstructive pulmonary disease (COPD), but its use remains controversial, mainly due to its narrow therapeutic window. Doxofylline, another xanthine, is an effective bronchodilator and displays a better safety profile than theophylline. Therefore, we performed a quantitative synthesis to compare the efficacy and safety profile of different xanthines in COPD.The primary end-point of this meta-analysis was the impact of xanthines on lung function. In addition, we assessed the risk of adverse events by normalising data on safet
APA, Harvard, Vancouver, ISO, and other styles
2

Cicero, Arrigo F. G., Federica Fogacci, Masanari Kuwabara, and Claudio Borghi. "Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update." Medicina 57, no. 1 (January 10, 2021): 58. http://dx.doi.org/10.3390/medicina57010058.

Full text
Abstract:
This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that f
APA, Harvard, Vancouver, ISO, and other styles
3

Cicero, Arrigo F. G., Federica Fogacci, Masanari Kuwabara, and Claudio Borghi. "Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update." Medicina 57, no. 1 (January 10, 2021): 58. http://dx.doi.org/10.3390/medicina57010058.

Full text
Abstract:
This article aims to critically review the evidence on the available therapeutic strategies for the treatment of hyperuricemia. For this reason, several papers were reviewed. Xanthine oxidase inhibitors are the safest and most effective uric acid lowering drugs for the management of chronic hyperuricemia, while the efficacy of uricosuric agents is strongly modulated by pharmacogenetics. Emergent drugs (lesinurad, peglotidase) were found to be more effective for the acute management of refractory hyperuricemia, but their use is supported by a relatively small number of clinical trials so that f
APA, Harvard, Vancouver, ISO, and other styles
4

Ahmad, Saeed, Ejaz Mohiuddin, Syed Muhammad Ali Shah, Muhammad Akram, Muhammad Amjad, Jaweria Nisar, Muhammad Riaz, Naveed Munir, and Ghulam Rasool. "Therapeutic Efficacy of Urinile Against Gouty Arthritis." Dose-Response 18, no. 4 (October 1, 2020): 155932582094693. http://dx.doi.org/10.1177/1559325820946934.

Full text
Abstract:
Gout is arthritis caused due to Monosodium urate (MSU) crystals deposition occurring particularly in patients with associated comorbidities limiting the use of conventional therapies. This study was planned to evaluate the therapeutic efficacy of urinile (a herbal drug) for the treatment of gouty arthritis. Allopurinol was used as standard drug (positive control). The study population of 250 volunteers (gouty arthritis patients) were divided into 2 groups as test and control group (n = 125 each). Gouty arthritis patients in test and control group were treated with 300 mg each of urinile and al
APA, Harvard, Vancouver, ISO, and other styles
5

Shen, Z., C. Colton, R. Yan, E. Polvent, V. Hingorani, S. Yan, and L. T. Yeh. "POS1128 COMBINATION TREATMENT OF AR882, A NEW URAT1 INHIBITOR, AND XANTHINE OXIDASE INHIBITORS ALLOPURINOL OR FEBUXOSTAT: EFFECT ON URIC ACID, HYPOXANTHINE AND XANTHINE IN PLASMA OR SERUM AND URINE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 843.2–843. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1215.

Full text
Abstract:
Background:Xanthine oxidase inhibitors (XOI) are commonly used as urate lowering therapy (ULT) for the treatment of gout. Allopurinol, the first-line treatment, demonstrates low response rate (< 40%), defined as serum urate (sUA) lowering effect below 6 mg/dL, in multiple large-scale clinical trials. As recommended in EULAR guidelines and other literatures, targeting sUA <5 mg/dL or even <4 mg/dL, provides a better opportunity to lower incidence of gout flare and resolution of tophi in gout patients. Febuxostat, a more potent XOI, has been classified as a second-line ULT agent due to
APA, Harvard, Vancouver, ISO, and other styles
6

Aouffen, M'hammed, Joanne Paquin, Eric De Grandpré, Réginald Nadeau, and Mircea-Alexandru Mateescu. "Deglycosylated ceruloplasmin maintains its enzymatic, antioxidant, cardioprotective, and neuronoprotective properties." Biochemistry and Cell Biology 79, no. 4 (August 1, 2001): 489–97. http://dx.doi.org/10.1139/o01-125.

Full text
Abstract:
Ceruloplasmin (CP), an important serum antioxidant, is a blue copper glycoprotein with ferroxidase and oxidase activities. Among other physiological actions, plasma CP was shown to protect isolated rat hearts and cultured P19 neurons exposed to oxidative stress conditions, raising the possibility of using this protein in the treatment of cardiac and neuronal diseases related to oxidative damage. However, since therapeutic applications of CP must be compatible with restrictions in the administration of blood derivatives to humans, there is a need to produce the protein by genetic engineering. T
APA, Harvard, Vancouver, ISO, and other styles
7

Munteanu, Mircea, Adrian Sturza, Adalbert Schiller, and Romulus Timar. "Endothelial Dysfunction in Diabetes – Clasic Sources of Vascular Oxidative Stress (Nadph Oxidases, Enos Uncoupling and Xanthine Oxidase)." Romanian Journal of Diabetes Nutrition and Metabolic Diseases 20, no. 2 (June 1, 2013): 149–55. http://dx.doi.org/10.2478/rjdnmd-2013-0019.

Full text
Abstract:
Abstract Cardiovascular disease is the leading cause of disease / mortality worldwide. It is generally accepted that increased production of reactive oxygen species (ROS) has an important role in cardiovascular pathology, contributing to endothelial dysfunction and to the aggravation of atherosclerosis. Among all cardiovascular risk factors, diabetes mellitus is one of the most important. The worldwide prevalence of diabetes has increased rapidly even in developing countries, doubling the combined risk of cardiovascular events in patients with hypertension. In diabetes, increased reactive oxyg
APA, Harvard, Vancouver, ISO, and other styles
8

Mozgovaya, E., S. Bedina, A. Trofimenko, M. Mamus, S. Spitsina, and I. Zborovskaya. "AB0061 ALTERATIONS OF XANTHINE OXIDOREDUCTASE ACTIVITY IN RED BLOOD CELLS AFTER GLUCOCORTICOID TREATMENT IN RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1062.1–1062. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3168.

Full text
Abstract:
Background:According to modern concepts, rheumatoid arthritis (RA) refers to severe autoimmune rheumatic diseases. The activation of free radical oxidation processes is essential in the development of this disease [1]. Xanthine oxidoreductase is a significant reactive oxygen species source [2]. Despite the great advances in the treatment of rheumatoid arthritis (RA) associated with the introduction of innovative drugs and especially the improvement of the strategy for their use into clinical practice, glucocorticoids still remain an important component of RA pharmacotherapy in actual clinical
APA, Harvard, Vancouver, ISO, and other styles
9

Mokra, Daniela, and Juraj Mokry. "Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?" International Journal of Molecular Sciences 22, no. 4 (February 16, 2021): 1929. http://dx.doi.org/10.3390/ijms22041929.

Full text
Abstract:
Despite progress in understanding the pathophysiology of acute lung damage, currently approved treatment possibilities are limited to lung-protective ventilation, prone positioning, and supportive interventions. Various pharmacological approaches have also been tested, with neuromuscular blockers and corticosteroids considered as the most promising. However, inhibitors of phosphodiesterases (PDEs) also exert a broad spectrum of favorable effects potentially beneficial in acute lung damage. This article reviews pharmacological action and therapeutical potential of nonselective and selective PDE
APA, Harvard, Vancouver, ISO, and other styles
10

Auberval, Nathalie, Stéphanie Dal, William Bietiger, Elodie Seyfritz, Jean Peluso, Christian Muller, Minjie Zhao, et al. "Oxidative Stress Type Influences the Properties of Antioxidants Containing Polyphenols in RINm5F Beta Cells." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/859048.

Full text
Abstract:
Thein vitromethods currently used to screen bioactive compounds focus on the use of a single model of oxidative stress. However, this simplistic view may lead to conflicting results. The aim of this study was to evaluate the antioxidant properties of two natural extracts (a mix of red wine polyphenols (RWPs) and epigallocatechin gallate (EGCG)) with three models of oxidative stress induced with hydrogen peroxide (H2O2), a mixture of hypoxanthine and xanthine oxidase (HX/XO), or streptozotocin (STZ) in RINm5F beta cells. We employed multiple approaches to validate their potential as therapeutic
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Xanthines – therapeutic use"

1

Duckworth, Megan Jane Medical Sciences Faculty of Medicine UNSW. "Characterisation of the xanthineguanine phosphoribosyltransferase of helicobacter pylori as a potential therapeutic target." Publisher:University of New South Wales. Medical Sciences, 2008. http://handle.unsw.edu.au/1959.4/43418.

Full text
Abstract:
Helicobacter pylori infects more than half of the global population and causes gastric disorders. The increasing development of antibiotic resistance by the bacterium continues to limit treatment options. The identification and characterisation of novel therapeutic targets are necessary for successful future treatment of the infection. One potential target for therapeutic intervention is the gpt gene encoded by hp0735 (jhp0672) in H. pylori strain 26695 (J99). This gene produces a putative xanthine-guanine phosphoribosyltransferase (XGPRTase), an enzyme of the purine salvage synthesis pathway
APA, Harvard, Vancouver, ISO, and other styles
2

"Evaluation of xanthine oxidase inhibitory and antioxidant activities of compounds from natural sources." 2005. http://library.cuhk.edu.hk/record=b5892399.

Full text
Abstract:
Lam Rosanna Yen Yen.<br>Thesis submitted in: September 2004.<br>Thesis (M.Phil.)--Chinese University of Hong Kong, 2005.<br>Includes bibliographical references (leaves 142-154).<br>Abstracts in English and Chinese.<br>Abstract --- p.i<br>Chinese Abstract --- p.iii<br>Acknowledgements --- p.v<br>Table of Contents --- p.vi<br>List of Abbreviations --- p.xii<br>List of Figures --- p.xv<br>List of Tables --- p.xix<br>Chapter Chapter 1 --- Introduction --- p.1<br>Chapter 1.1 --- Reactive oxygen species --- p.1<br>Chapter 1.1.1 --- Intracellular sources of ROS --- p.1<br>Chapter 1.1.2 ---
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Xanthines – therapeutic use"

1

1946-, Barnes Peter J., ed. The Mechanism of action of Xanthines in respiratory disease. London: Royal Society of Medicine Services, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

(Editor), K. E. Andersson, and C.G.A. Persson (Editor), eds. Anti-asthma Xanthines and Adenosine (Current clinical practice series). Elsevier, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Karl-Erik, Andersson, Persson C. G. A, and AB Draco, eds. Anti-asthma xanthines and adenosine: Proceedings of a symposium in Copenhagen, February 22-23, 1985. Amsterdam: Excerpta Medica, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1944-, Costello J. F., Piper Priscilla J, and Royal Society of Medicine (Great Britain). Respiratory Section., eds. Methylxanthines and phosphodiesterase inhibitors in the treatment of airways disease: The proceedings of a meeting held by the Respiratory Section of the Royal Society of Medicine, London, November 1993. London: Parthenon Pub. Group, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Xanthines – therapeutic use' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography